<DOC>
	<DOCNO>NCT01334203</DOCNO>
	<brief_summary>This study evaluate efficacy ranolazine compare placebo duration exercise assess exercise tolerance testing ( ETT ) anticipate peak ranolazine plasma concentration 12 week treatment subject chronic stable angina coronary artery disease ( CAD ) history type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>A Study Effects Ranolazine Exercise Duration Subjects With Chronic Stable Angina Coronary Artery Disease ( CAD ) With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>This study evaluate efficacy ranolazine compare placebo duration exercise assess exercise tolerance testing ( ETT ) anticipate peak ranolazine plasma concentration 12 week treatment subject chronic stable angina coronary artery disease ( CAD ) history type 2 diabetes mellitus ( T2DM ) . This randomized , double-blind , placebo-controlled , parallel group study subject chronic stable angina CAD receive stable dose single concomitant antianginal medication also history T2DM ; allow antianginals beta-blocker ( atenolol metoprolol ) calcium-channel blocker .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Written inform consent Males females age 18 79 year Able perform Sheffield Modified Bruce Treadmill Exercise Protocol At least 3months history chronic stable angina trigger physical effort relieve rest and/or sublingual nitroglycerin Coronary artery disease document one following : Angiographic evidence ≥ 50 % stenosis one major coronary artery History myocardial infarction ( MI ) document positive CKMB enzyme , troponins , ECG change Cardiac nuclear scan study diagnostic CAD , e.g. , thallium scan ECHO stress pharmacologic intervention ( adenosine , dipyridamole , etc . ) Stable treatment one follow antianginal medication least 4 week prior Screening : betablocker ( atenolol 50 mg daily metoprolol 100 mg daily ) dihydropyridine calciumchannel blocker ( amlodipine 5 mg daily nifedipine 30 mg daily ) nondihydropyridine calciumchannel blocker ( diltiazem 180 360 mg daily verapamil 180 360 mg daily ) Willingness discontinue antianginals treat one allow antianginal therapy Documented history type 2 diabetes mellitus Females childbearing potential must agree utilize highly effective contraception method Screening throughout duration study treatment 14 day follow last dose study drug . Inability exercise exercise limitation due comorbidities may interfere ability perform require ETT ( e.g. , morbid obesity , significant chronic lung disease , prior hospitalization acute exacerbation chronic lung disease home oxygen use , chronic oral steroid therapy limit exercise capacity , osteoarthritis , peripheral artery disease , etc . ) Any absolute contraindication ETT Presence electrocardiographic abnormality interfere ECG interpretation may cause false positive stress test ( e.g. , ≥ 1 mm horizontal downsloping ST segment depression rest standard ECG lead , LownGanongLevine syndrome , WolffParkinsonWhite syndrome , leave bundle branch block , leave ventricular hypertrophy repolarization abnormality , ventricular pacemaker , etc . ) Decompensated heart failure Clinically significant valvular heart disease congenital cardiac defect Acute coronary syndrome prior 2 month coronary revascularization within prior 6 month plan coronary revascularization study period Stroke transient ischemic attack within 6 month prior Screening History serious ventricular dysrhythmias history lifethreatening ventricular arrhythmia Atrial fibrillation QTc &gt; 0.5 second Hypertrophic cardiomyopathy Uncontrolled hypertension ( seat systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 110 mm Hg ) Systolic blood pressure &lt; 90 mm Hg Inability discontinue current antianginal medication remain one allow antianginal therapy Clinically significant hepatic impairment Creatinine clearance ( CLCr ) &lt; 30 ml/min Prior treatment ranolazine Participation another investigational drug device study within 1 month prior Screening Females breastfeed Positive serum pregnancy test Current treatment potent inhibitor CYP3A ( e.g. , ketoconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir , saquinavir ) Current treatment CYP3A P glycoprotein ( Pgp ) inducer ( e.g. , rifampicin/rifampin , carbamazepine , St. John 's wort ) History illicit drug use alcohol abuse within one year screen Any condition , opinion investigator , likely prevent compliance study protocol pose safety concern subject participates study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Chronic angina</keyword>
	<keyword>Angina pectoris</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>ETT</keyword>
</DOC>